Bristol-Myers Squibb Co (NYSE:BMY) – Research analysts at William Blair issued their Q1 2019 earnings estimates for Bristol-Myers Squibb in a research note issued to investors on Tuesday. William Blair analyst M. Phipps forecasts that the biopharmaceutical company will earn $0.95 per share for the quarter. William Blair also issued estimates for Bristol-Myers Squibb’s Q2 2019 earnings at $0.97 EPS, Q3 2019 earnings at $0.98 EPS, Q4 2019 earnings at $1.00 EPS, FY2019 earnings at $3.91 EPS and FY2020 earnings at $4.42 EPS.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.67 by $0.01. The company had revenue of $5.45 billion for the quarter, compared to analyst estimates of $5.35 billion. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 33.68%. The company’s revenue was up 3.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.63 earnings per share.

Other equities analysts have also issued reports about the stock. Vetr lowered shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $60.72 price objective on the stock. in a research report on Thursday. Piper Jaffray Companies reissued a “hold” rating and issued a $60.00 price objective on shares of Bristol-Myers Squibb in a research report on Friday, October 27th. Leerink Swann increased their price objective on shares of Bristol-Myers Squibb from $71.00 to $76.00 and gave the company a “positive” rating in a research report on Tuesday. BMO Capital Markets decreased their price target on shares of Bristol-Myers Squibb from $52.00 to $51.00 and set an “underperform” rating on the stock in a research note on Tuesday. Finally, Jefferies Group downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $72.00 price target on the stock. in a research note on Monday, October 16th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $65.58.

Shares of Bristol-Myers Squibb (NYSE BMY) traded up $0.01 on Wednesday, hitting $62.70. 11,131,473 shares of the stock traded hands, compared to its average volume of 8,714,557. The company has a market capitalization of $102,620.00, a price-to-earnings ratio of 106.27, a PEG ratio of 1.95 and a beta of 1.08. Bristol-Myers Squibb has a 52 week low of $51.52 and a 52 week high of $66.10. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46.

A number of institutional investors have recently made changes to their positions in BMY. River Wealth Advisors LLC acquired a new stake in shares of Bristol-Myers Squibb in the 2nd quarter valued at approximately $218,000. S&CO Inc. boosted its stake in shares of Bristol-Myers Squibb by 1.7% in the 2nd quarter. S&CO Inc. now owns 391,567 shares of the biopharmaceutical company’s stock valued at $21,818,000 after purchasing an additional 6,701 shares in the last quarter. Ingalls & Snyder LLC boosted its stake in shares of Bristol-Myers Squibb by 3.1% in the 2nd quarter. Ingalls & Snyder LLC now owns 198,263 shares of the biopharmaceutical company’s stock valued at $11,047,000 after purchasing an additional 5,910 shares in the last quarter. Essex Investment Management Co. LLC boosted its stake in shares of Bristol-Myers Squibb by 20.5% in the 2nd quarter. Essex Investment Management Co. LLC now owns 23,676 shares of the biopharmaceutical company’s stock valued at $1,319,000 after purchasing an additional 4,029 shares in the last quarter. Finally, Papp L Roy & Associates boosted its stake in shares of Bristol-Myers Squibb by 23.2% in the 2nd quarter. Papp L Roy & Associates now owns 6,900 shares of the biopharmaceutical company’s stock valued at $384,000 after purchasing an additional 1,300 shares in the last quarter. Hedge funds and other institutional investors own 69.70% of the company’s stock.

In other Bristol-Myers Squibb news, EVP Sandra Leung sold 156,582 shares of the stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the sale, the executive vice president now directly owns 584,373 shares in the company, valued at $37,031,717.01. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Theodore R. Samuels II acquired 4,000 shares of Bristol-Myers Squibb stock in a transaction on Friday, December 15th. The shares were purchased at an average price of $62.30 per share, for a total transaction of $249,200.00. Following the completion of the purchase, the director now directly owns 22,000 shares of the company’s stock, valued at $1,370,600. The disclosure for this purchase can be found here. Corporate insiders own 0.23% of the company’s stock.

The firm also recently declared a quarterly dividend, which was paid on Thursday, February 1st. Investors of record on Friday, January 5th were paid a $0.40 dividend. The ex-dividend date of this dividend was Thursday, January 4th. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 annualized dividend and a dividend yield of 2.55%. Bristol-Myers Squibb’s dividend payout ratio is 271.19%.

WARNING: This piece of content was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.dailypolitical.com/2018/02/09/william-blair-comments-on-bristol-myers-squibb-cos-q1-2019-earnings-bmy.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Earnings History and Estimates for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.